Bionano Genomics Launches $10 Million Public Offering

Bionano Genomics, Inc. (NASDAQ:BNGO) is among the best fundamentally strong penny stocks to buy right now. Bionano Genomics, Inc. (NASDAQ:BNGO) has launched a public offering of 5 million shares, priced at $2.00 per share. This offering of both Series E and short-term Series F warrants is anticipated to generate $10 million in gross proceeds. If the warrants are fully exercised, the company could raise an additional $20 million.

Intended to support general corporate needs, these funds will provide a solid foundation for Bionano Genomics, Inc. (NASDAQ:BNGO). The company’s plans to expand into clinical and anatomic pathology aren’t something hidden. While emphasizing routine users of the company’s optical genome mapping (OGM) and VIA software across new instrument placements, the strategic efforts of September 2024 have already started to bear fruit.

What’s truly noteworthy is the strategy that Bionano Genomics, Inc. (NASDAQ:BNGO) has adopted. The company is now focused on enhancing utilization among routine users, strengthening the already installed base, accelerating VIA adoption, and developing reimbursement support for OGM. It plans to do so to expand profits and reduce costs.

Bionano Genomics, Inc. (NASDAQ:BNGO), based in San Diego, California, is a provider of genome analysis solutions. Founded in 2003, the company is dedicated to transforming the world’s view of the genome.

While we acknowledge the potential of BNGO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.